May 14 (Reuters)-
Brightpath Biotherapeutics Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 0 mln 1 mln 0 mln
(-92.6 pct)
Operating loss 1.30 loss 1.16 loss 1.97
Recurring loss 1.29 loss 1.15 loss 1.95
Net loss 1.30 loss 1.15 loss 1.95
EPS loss 11.70 yen loss 14.12 yen loss 13.24 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Brightpath Biotherapeutics Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T